Nvidia, Eli Lilly plan AI drug innovation lab
Digest more
Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...
Eli Lilly’s presence in France has spanned more than six decades, but rumors of an acquisition suggest the pharmaceutical ...
Barchart on MSN
What to Expect From Eli Lilly’s Q4 2025 Earnings Report
Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its ...
Eli Lilly's research and development head said on Monday the company will have plenty of supply to launch its ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.
Humana’s CenterWell pharmacy will dispense GLP-1 weight loss drugs made by Eli Lilly as part of a new program for employers ...
France's Finance Ministry said on Monday it had received no formal request for investment approval regarding French biotech ...
It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...
Eli Lilly & Co. said Monday it expects its highly anticipated weight-loss pill to receive US regulatory approval as early as ...
Jan 8 () - Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback